Body mass index, PAM50 subtype, recurrence, and survival among patients with nonmetastatic breast cancer

• Published in: Cancer 2017-07, Vol.123 (13), p.2535-2542
• Main Authors: Cespedes Feliciano, Elizabeth M., Kwan, Marilyn L., Kushi, Lawrence H., Chen, Wendy Y., Weltzien, Erin K., Castillo, Adrienne L., Sweeney, Carol, Bernard, Philip S., Caan, Bette J.
• Format: Article
• Language: English
• Subjects: Adult; Age; Aged; Body mass; Body Mass Index; Body weight; Breast cancer; breast cancer subtype; Breast Neoplasms - genetics; Breast Neoplasms - mortality; Breast Neoplasms - pathology; Breast Neoplasms - therapy; California - epidemiology; Cancer; Chemotherapy; Comorbidity; Confidence intervals; Death; DNA microarrays; Epidermal growth factor; Fatalities; Female; Gene expression; Health risk assessment; Health risks; Heterogeneity; Humans; Intervention; Menopause; Middle Aged; Minority & ethnic groups; molecular classification; Mortality; Neoplasm Recurrence, Local - epidemiology; Neoplasm Staging; Obesity; Obesity - epidemiology; Oncology; Overweight; Overweight - epidemiology; Patients; Precision medicine; Prediction Analysis of Microarray 50 (PAM50) gene expression assay; Prognosis; Proportional Hazards Models; Receptor, ErbB-2 - metabolism; Receptors, Estrogen - metabolism; Receptors, Progesterone - metabolism; recurrence; Regression analysis; Retrospective Studies; Risk Factors; Survival; Survival Rate; Transcriptome; Tumors; Weight control; Womens health
• ISSN: 0008-543X; 1097-0142
• DOI: 10.1002/cncr.30637

BACKGROUND Studies of obesity and survival among patients with breast cancer produce conflicting results, possibly because of heterogeneity by molecular subtype. METHODS This study examined whether the association of body mass index (BMI) at diagnosis with breast cancer recurrence and survival varied across subtypes defined by PAM50 (Prediction Analysis of Microarray 50) gene expression. Included were 1559 Kaiser Permanente Northern California members ages 18 to 79 years who had PAM50 assays and were diagnosed with American Joint Committee on Cancer stage I through III breast cancer from 1996 to 2013. Patients reported weight and height. Cox regression models were adjusted for age, menopause, race/ethnicity, stage, and chemotherapy. RESULTS Over a median of 9 years (maximum, 19 years), 378 women developed recurrent disease, and 312 died from breast cancer. Overall, BMI was not associated with breast cancer recurrence or survival when controlling for subtype (eg, the hazard ratio per 5 kg/m2 of BMI was 1.05 [95% confidence interval, 0.95‐1.15] for breast cancer‐specific death). However, associations varied by subtype. Among women with luminal A cancers, those who had class II/III obesity, but not class I obesity or overweight, had worse outcomes. When women who had a BMI ≥35 kg/m2 were compared with those who had a BMI from 18.5 to